Syndax Pharmaceuticals Inc — Director's Dealing 2021

Sep 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-09-27

Reporting Person: Metzger Michael A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-27	Common Stock	M	24437.00	$7.20	Acquired	42096.00	Direct
2021-09-27	Common Stock	S	24437.00	$19.5127	Disposed	17659.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-27	Stock Options (Right to buy)	$7.20	M	24437.00	Disposed	2025-06-01	Common Stock (24437.00)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2: The sales price ranged from $19.02 to $19.96

F3: This option is fully vested.